http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103113381-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caacf483b6be9ae2d2677103a70559db |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22 |
| filingDate | 2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05aa463e87a1efd57f985491a553938 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8dc13b8743cfe875a7ec5304f428328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5030e84147d5f9c08fe39c2ec8a54ffb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12ce24a176a45bb24cd3f684d0b24eda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25b8c489a629b2bbe0a65b6ad102ca80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_961e4b5cf98710ad9d146092dae35b7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9445e9e2921244e2eb367ff09391b95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6917a090fe22f6f51e7cb794d2e024d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a20f6222eb121a87d19b42ffc0ba5e49 |
| publicationDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103113381-B |
| titleOfInvention | Serial water-soluble hydroxycamptothecine naphthenic amino alcohol derivative and preparation method and use thereof |
| abstract | The invention discloses serial water-soluble hydroxycamptothecine naphthenic amino alcoholderivative. The serial water-soluble hydroxycamptothecine naphthenic amino alcohol derivative is synthesized by leading naphthenic amino alcohol methylene into a hydroxycamptothecine structure for the first time; and the hydroxycamptothecine with strong cell toxicity is decorated into the hydroxycamptothecine naphthenic amino alcohol derivative with medium cell toxicity. Therefore, the selectivity of induction of tumor cell apoptosis is improved; the situation that the hydroxycamptothecine prolinol has special hydrogenation reduction metabolic pathway in the body is found out for the first time; existing camptothecin derivatives do not have special hydrogenation reduction metabolic pathway; and active oxygen in the cell can be controlled, so as to inhibit cell proliferation, selectively induce cancer cell apoptosis, and inhibit cell inflammatory necrosis. Normal cell function is not affected. |
| priorityDate | 2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 308.